Clinical Trial Update: A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of TH-302 in combination with sunitinib for neuroendocrine pancreatic tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors
• Pancreatic Neoplasms

Drugs mentioned

• Sunitinib (sunitinib)
• TH-302 (evofosfamide)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Neuroendocrine Tumors, Pancreatic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2020-07-27